Increased mortality and perioperative complications in patients with previous elective percutaneous coronary interventions undergoing coronary artery bypass surgery  by Bonaros, Nikolaos et al.
Acquired Cardiovascular Disease Bonaros et al
A
C
DIncreased mortality and perioperative complications in patients with
previous elective percutaneous coronary interventions undergoing
coronary artery bypass surgery
Nikolaos Bonaros, MD,a Diana Hennerbichler, MD,a Guy Friedrich, MD,b Alfred Kocher, MD,a Otmar Pachinger, MD,b
Gu¨nther Laufer, MD,a and Johannes Bonatti, MDa
Objective: The relationship between previous percutaneous coronary intervention and perioperative outcome
after coronary artery bypass grafting remains undetermined. The aim of the study was to investigate whether
previous elective percutaneous coronary intervention influences the outcome of elective coronary artery bypass
grafting.
Methods: Between 2002 and 2007, 4412 consecutive patients underwent first-time open surgery at the Innsbruck
Medical University. After excluding patients with a history of emergency percutaneous coronary intervention, we
isolated 306 patients with elective percutaneous coronary intervention during the last 24 months before isolated
coronary artery bypass grafting (group 1). Those patients were compared with 452 consecutive age-, gender-, and
EuroSCORE-matched patients without a history of percutaneous coronary intervention (group 2), in terms of
30-day mortality, major adverse cardiac events, and perioperative complications.
Results: Both groups were comparable concerning preoperative linear EuroSCORE (group 1: 4.83 0.18, group
2: 4.72  0.14, P ¼ .63). Patients who underwent previous elective percutaneous coronary intervention before
coronary artery bypass grafting had an increase in perioperative mortality (group 1: 4.4% vs group 2: 2.4%,
P< .001) and major adverse cardiac events (group 1: 7.9% vs 4.3%, P< .001). In addition, the incidence of
bleeding complications (group 1: 5.9% vs group 2: 3.8%, P ¼ .017) and the number of blood products (group
1: 1.70 0.31 vs 0.61 0.17, P<.001) used were higher in patients of group 1. A higher incidence of acute renal
failure (5.9% vs 2.7%, P ¼ .025) and renal replacement therapy (3.6% vs 1.7%, P ¼ .03) was observed in
patients of group 1.
Conclusion: Patients with a history of elective percutaneous coronary intervention before referral to coronary
artery bypass grafting have a worse perioperative outcome in terms of mortality, major adverse cardiac events,
and perioperative complications compared with patients without a history of percutaneous coronary intervention.
This fact should be considered in risk stratification for patients who are scheduled for elective coronary artery
bypass grafting.The number of percutaneous coronary interventions (PCIs)
has been continuously increasing during the last 15 years.1
PCI represents the main revascularization strategy in acute
myocardial infarction,2 and cardiac interventionalists have
gained significant experience with the interventional treat-
ment of triple-vessel disease even in high-risk patients.3
However, despite several improvements in PCI technology
there is increasing evidence proving the inferiority of mid-
and long-term results after PCI compared with coronary ar-
tery bypass grafting (CABG) even in the drug-eluting stent
era.4,5 PCI, even if primarily successful, is associated with
target lesion restenosis or target vessel restenosis mainly
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proximately 10% to 20% of the patients with previous
PCI are referred to CABG within 3 to 5 years after primary
intervention.7
Evidence accumulated from patients who underwent non-
cardiac surgery indicates that a history of PCI is associated
with a higher incidence of perioperative adverse cardiac
events.8,9 The outcome of CABG in patients with previous
PCI still remains unexplored. Initial results demonstrated
that previous PCI had no influence on perioperative outcome
after CABG, provided that PCI was successful and no resid-
ual stenosis was left.10 A more detailed analysis including
approximately 300 patients provided evidence that the peri-
operative outcome in patients with a history of repeat PCI
who undergo CABG is significantly worse in terms of mor-
tality and morbidity compared with patients with a history of
a single PCI preoperatively.11 Because previous studies
were designed to investigate multiple PCI before CABG
and did not exclude acute interventions and cases with in-
complete revascularization, the question whether the perio-
perative outcome after CABG is influenced by previous
elective PCI remains unanswered.rgery c April 2009




CABG ¼ coronary artery bypass grafting
IABP ¼ intraaortic balloon pump
ICU ¼ intensive care unit
MACE ¼ major adverse cardiac event
PCI ¼ percutaneous coronary intervention
The aim of the present study was to investigate whether pa-
tients referred to CABG after previous elective PCI differ
from patients without a history of PCI in terms of perioper-
ative mortality and morbidity.
MATERIALS AND METHODS
Patient Groups
Between January 2002 and May 2007, 4412 consecutive patients under-
went open surgery at the Innsbruck Medical University. All consecutive pa-
tients with a history of PCI who underwent primary isolated CABG (group
1, n¼ 306) between January 2002 and May 2007 were retrospectively com-
pared with an age-, gender-, and risk-adjusted cohort of patients without
a history of PCI who underwent CABG during the same time frame (group
2, n ¼ 452). Patients with (1) an indication for cardiac operation other than
isolated CABG (on an intent-to-treat basis), (2) cardiac reoperation, (3) a his-
tory of emergency or salvage PCI, (4) a time interval of PCI to CABG more
than 24 months, (5) hybrid cases after PCI as a first act to a planned hybrid
procedure, and (6) primary PCI failure were excluded from the analysis
(Table 1). Risk adjustment was performed by means of predicted linear and
logistic EuroSCORE risk stratification of the study group. Patients’ age,
gender, and linear EuroSCORE were used for matching between the groups.
Data Collection
Data used in the analysis were collected from the institutional database
from the Department of Cardiac Surgery, Innsbruck Medical University,
which was based on the data collected using the Data Collection form of
the Society of Thoracic Surgeons (Adult Cardiac Surgery Database Data
Collection form Version 2.25.1). Patients were followed by contacting the
family practitioners or themselves directly.
Study End Points
The primary end points of the study12 included perioperative and 30-day
mortality defined as the incidence of death episodes during hospitalization
for surgery or up to 30 days after CABG.
The secondary end points included the following parameters of perioper-
ative outcome:
 The use of blood products intraoperatively and postoperatively was de-
fined as the number of red blood cells, fresh-frozen plasma, or platelet
units used during and after the operation, respectively.
 Ventilation time was defined as the duration of ventilation needed post-
operatively, including the potential need for additional ventilation after
reintubation.
 Intensive care unit (ICU) stay was defined as the duration of ICU stay
needed after the operation, including the potential need for additional
ICU stay after readmission.
 Total length of stay was defined as the duration of postoperative stay at
the Innsbruck Medical University, including stay at the ICU, intermediate
care unit, and normal ward.
 Perioperative myocardial infarction was defined as the development of
new persistent ST-segment, T- or Q-wave changes in electrocardiogram,
new left bundle branch block, or troponin T elevation above the 53 99thThe Journal of Thoracic and Cpercentile of the upper reference limit or creatinine kinase-MB/creatinine
kinase ratio of greater than 10%.13
 Major adverse cardiac event (MACE) was defined as the combined end
point of death, perioperative myocardial infarction, or need for repeat
revascularization.
 Low cardiac output syndrome was presumed in patients with a cardiac in-
dex less than 2.2 L/min/m2 or a mean arterial pressure less than 60 mm
Hg, despite high-dose inotropic support (intravenously administered do-
pamine>8 mg/kg/min, epinephrine>0.1 mg/kg/min, or norepinephrine
>0.1 mg/kg/min).14
 Death was considered of cardiac origin if it was caused by perioperative
myocardial infarction, significant cardiac arrhythmias, or refractory low
cardiac output syndrome.
 Need for intraaortic balloon pump (IABP) was defined as any use of IABP
after establishing cardiopulmonary bypass or at the postoperative phase.
 Postoperative atrial fibrillation was defined as any new episode of atrial
fibrillation documented on online monitoring or electrocardiogram dur-
ing the postoperative period.
 Postoperative renal failure was defined as any new onset of hemofiltration
or dialysis or any increase in creatinine levels more than 0.5 mg/dL above
the preoperative level.15
 Need for renal replacement therapy was defined as any incidence of new
hemofiltration or dialysis postoperatively.
 Reoperation for bleeding was defined as any incidence of reoperation
needed for bleeding complications.
 Initial ventilation time was defined as the duration of ventilation at the
ICU (in case of need for reintubation, an additional ventilation time
was calculated).
 In-hospital complications were defined as the combined end point of
MACE, need for IABP, reintubation, readmission to the ICU, neurologic
complications, renal failure, and need for renal replacement therapy or re-
operation for bleeding during the postoperative phase and until discharge.
Perioperative Management
Platelet anti-aggregation agents were discontinued in all patients with the
exception of patients with (1) left main stenosis, (2) unstable angina, or (3)
TABLE 1. Patient groups
4412 consecutive patients underwent
cardiac procedures at theDepartment of
Cardiac Surgery, Innsbruck Medical





306 patients with history
of elective PCI during
the last 2 years






Group 1 Group 2
Age, gender and risk
matching
CABG, Coronary artery bypass grafting; PCI, percutaneous coronary intervention;
PTCA, percutaneous coronary angioplasty.ardiovascular Surgery c Volume 137, Number 4 847
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Dprior implantation of bare mental stent up to 3 months preoperatively or prior
implantation of drug-eluting stent up to 12 months preoperatively. Oral anti-
coagulation was converted to low molecular heparin at least 5 days before
scheduled CABG. On-pump CABG was performed under full hepariniza-
tion with 300 IU/kg heparin that was antagonized with protamine sulphate
in a 1:1 relation; 2.6% of the PCI group and 2.9% of the non-PCI group un-
derwent off-pump operation. Full-dose aprotinin was used intraoperatively
in all patients studied. Standard cardiopulmonary bypass was used in most
cases, and St Thomas II cold cardioplegia was used mixed with blood in
a 4:1 relation. Dual aortic crossclamp was used in the majority of the pa-
tients, except for patients with significant atherosclerosis of the ascending
aorta. Postoperative antiplatelet therapy included administration of salicylic
acid intravenously during the first 24 hours after the operation combined
with salicylic acid per os after extubation. Patients with contraindications
to aspirin received clopidogrel as long-term anti-aggregation regimen.
Statistical Analysis
Categoric variables are presented as absolute numbers and frequencies in
percentage and both groups were compared using the Pearson’s chi-square
test. Continuous variables were expressed as mean  standard deviation,
and the groups were compared by means of t test. Statistical analysis was per-
formed using the Statistical Package for the Social Sciences 15.0 (SPSS Inc,
Chicago, Ill). The authors had full access to the data and take responsibility
for data integrity. All authors agreed to the content of the article as written.
RESULTS
Patients’ Demographics and Preoperative and
Intraoperative Characteristics
As shown in Table 2, no differences in the demographic
data and preoperative characteristics were observed between
the study groups, with the exception of history of myocardial
infarction and use of platelet anti-aggregation. Both vari-
ables were observed more frequently in the PCI group. In
addition, preoperative ejection fraction was significantly
lower in this group (group 1: 46.4%  11.9% vs group 2:
54.7%  14.3%, P< .001), and approximately one third
of the patients experienced myocardial infarction at the inter-
val between PCI and CABG (Table 3) . It is noteworthy that
preoperative linear and logistic EuroSCORE levels were
comparable between the 2 groups (linear EuroSCORE PCI
group: 4.83  0.18, non-PCI group: 4.72  0.14, P ¼
.63), because the control group was matched to group 1 in
terms of age, gender, and EuroSCORE. Intraoperative data
in terms of the use and duration of cardiopulmonary bypass,
duration of aortic occlusion, total number of distal anasto-
mosis, and use of arterial and venous grafts were also com-
parable between the 2 groups (Table 4).
Mortality and Perioperative Outcome
As shown in Figure 1, perioperative mortality was signif-
icantly higher in the PCI group (14/306) compared with the
non-PCI group (11/452, 4.4% vs 2.4%, P< .001). Simi-
larly, analysis of 30-day mortality revealed more than
70% increased mortality rates in the first group compared
with the mortality rates of group 2 (10/306, 3.3% vs 8/
452, 1.8%, P< .001). Patients with prior PCI had a signifi-
cantly worse perioperative outcome (linear perioperative
outcome group 1: 1.44  0.26 vs group 2: 0.53  0.18,848 The Journal of Thoracic and Cardiovascular SuP ¼ .031, logistic perioperative outcome group 1: 2.33 
0.41 vs group 2: 1.26  0.39, P ¼ .044). There was no dif-
ference between the groups in terms of linear and logistic
predicted mortality (group 1: 4.8  3.1 vs group 2: 4.7 
3.0 for linear predicted mortality and group 1: 5.6  6.9
vs group 2: 5.4  6.4, for logistic predicted mortality).
Perioperative Myocardial Infarction and MACE
An approximately 4-fold increase in the incidence of peri-
operative myocardial infarction was observed in the PCI
group, which was accompanied with significantly higher
incidences of low cardiac output syndrome (Figure 2).
Accordingly, the need for IABP support was 4 times higher
in the first group. Analysis of the combined end point of
MACE revealed an approximately 2-fold increase in the
cohort of patients with prior PCI.
Perioperative Need for Blood Products and Bleeding
Complications
As shown in Table 3, the need for blood transfusions,
including red blood cells, fresh-frozen plasma, and platelet
concentrates, during and after the operation was significantly




(n ¼ 452) P value
Age (y) 64.6  10.0 67.6  10.5 P ¼ .152
Gender (M/F) 230/74 336/116 P ¼ .113
Risk factors for CAD
History of smoking 94 (30.7%) 139 (30.8%) P ¼ 1.000
Hyperlipidemia 250 (81.7%) 370 (81.9%) P ¼ .373
Hypertension 238 (77.7%) 385 (85.2%) P ¼ .572
Diabetes 60 (19.6%) 112 (24.8%) P ¼ .112
Family history of CAD 53 (17.3%) 66 (14.6%) P ¼ .309
Renal failure 12 (3.9%) 36 (8.0%) P ¼ .132
Dialysis 8 (2.6%) 5 (1.1%) P ¼ .159
Cerebrovascular accident 12 (3.9%) 25 (5.5%) P ¼ .391
Peripheral vascular disease 46 (15.0%) 62 (13.7%) P ¼ .598
Cerebrovascular disease 27 (8.8%) 47 (10.4%) P ¼ .534
Clinical manifestation
of CAD
Myocardial infarction 177 (57.8%) 170 (37.6%) P< .001
Congestive heart failure 55 (18.0%) 64 (14.2%) P ¼ .155
Stable angina 158 (51.6%) 237 (52.4%) P ¼ .652
Unstable angina 75 (24.5%) 112 (24.8%) P ¼ .376
Cardiogenic shock 5 (1.6%) 4 (0.9%) P ¼ .242
CV medication
Aspirin 279 (91.2%) 416 (92.0%) P ¼ .425
Aspirin until
day of operation
212 (69.3%) 187 (41.4%) P< .001
Clopidogrel 63 (20.6%) 43 (9.51%) P ¼ .004
Beta-blockers 227 (74.1%) 312 (69.0%) P ¼ .276
ACE antagonists 161 (52.6%) 234 (51.7%) P ¼ .168
Lipid lowering 231 (75.5%) 326 (72.1%) P ¼ .427
PCI, Percutaneous coronary intervention; CAD, coronary artery disease; CV, cardio-
vascular; ACE, angiotensin-converting enzyme.rgery c April 2009
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Dhigher in the PCI group. Accordingly, approximately 4 times
more patients in the PCI group underwent reoperation for
bleeding complications.
Perioperative Renal Failure and Need for New
Dialysis
The incidence of perioperative renal failure was signifi-
cantly higher in the study group. Twice as many patients
of this group required new renal replacement therapy during
the postoperative period.
Other Parameters Influencing Outcome
There was no difference noted between the 2 groups in
terms of ventilation time and ICU stay (Table 4). The total
postoperative length of stay, neurologic events, and inci-
dence of postoperative atrial fibrillation were also compara-
ble between the 2 study arms. However, analysis of the
cumulative end point in-hospital complications revealed
a significantly worse outcome in the PCI group compared
with patients without a history of PCI (43.2% vs 19.4%
respectively,P<.001). Diabetic patients have been included
in a separate analysis, which yielded similar results as dem-
onstrated for the whole patient population (Table 5).
DISCUSSION
We performed a retrospective analysis of 4412 consecu-
tive patients in terms of the outcome of surgical coronary re-
TABLE 3. Preoperative angiographic characteristics and predicted
mortality
PCI No PCI P value
No. of diseased vessels
1 18 (5.9%) 27 (6.0%) P ¼ .352
2 45 (14.7%) 65 (14.4%) P ¼ .168
3 241 (78.8%) 360 (79.6%) P ¼ .427
Left main stenosis 61 (19.9%) 90 (19.9%) P ¼ .372
Previous PCI with
any stent
298 (97.4%) 0 (0%) —
Previous PCI with
drug-eluting stent
118 (38.6%) 0 (0%) —








136 (44.4%) 0 (0%) —
Myocardial infarction
during the last 24 mo
101 (33.0%) 95 (21%) P ¼ .027
Log predicted mortality 5.6  6.9 5.4  6.4 P ¼ .663
Lin predicted mortality 4.8  3.1 4.7  3.0 P ¼ .633
EF preoperatively 46.4%  11.9% 54.7%  14.3% P< .001
Pulmonary artery
mean pressure (mm Hg)
21.9  6.3 22.3  8.1 P ¼ .547
PCI, Percutaneous coronary intervention; EF, ejection fraction.The Journal of Thoracic andvascularization in patients with and without a history of PCI.
To minimize bias, only patients with isolated coronary ar-
tery disease who had not undergone any previous cardiac
surgical procedure were eligible to the analysis. To achieve
comparable patient populations in the 2 study groups, all pa-
tients with a history of PCI to CABG interval more than 24
months were considered to be exposed to coronary artery
disease for a longer period; therefore, they were excluded
from the study. Our results demonstrate that patients with
prior PCI who undergo CABG have higher mortality and
periprocedural complication rates, which thus far is not pre-
dicted by currently available preoperative risk assessment
scores.
The current study demonstrated that both 30-day mortal-
ity and overall mortality were approximately 2 times higher
in patients with a history of PCI. This finding is consistent
with the results of Thielmann and colleagues,16 who re-
ported a 3 times higher incidence of perioperative mortality
after CABG in diabetic patients with triple-vessel disease
and a history of multiple PCI. The worse outcome after
CABG in the PCI group can be explained by several factors:
First, although the calculated EuroSCORE of these patients
is comparable to that of the control group, a higher incidence




(n ¼ 452) P value
Distal anastomoses (arteries) 1.24  0.71 1.21  0.69 P ¼ .511
Distal anastomoses (veins) 1.69  1.05 1.59  1.11 P ¼ .296
CPB time (min) 120  58 124  67 P ¼ .361
Crossclamp time (min) 66  35 73  40 P ¼ .129
OPCAB 8 (2.6%) 13 (2.9%) P ¼ .754
Intraoperative blood products 1.70  0.31 0.61  0.17 P< .001
Red blood cell units 1.03  0.21 0.42  0.11 P< .001
Fresh-frozen plasma units 0.58  0.13 0.18  0.03 P ¼ .003
Platelet units 0.12  0.02 0.07  0.01 P ¼ .015
Red blood cell units ICU 0.90  0.31 0.34  0.11 P ¼ .036
Fresh-frozen plasma units ICU 0.62  0.16 0.37  0.09 P ¼ .041
Platelet units ICU 0.10  0.02 0.08  0.01 P ¼ .074
Initial ventilation time (h) 26.5  118.3 26.9  86.1 P ¼ .960
Additional ventilation time (h) 14.7  110.7 7.0  46.0 P ¼ .055
Total ventilation time (h) 71.1  351.9 36.9  114.8 P ¼ .027
Initial ICU stay (h) 69.9  164.5 61.3  123.3 P ¼ .43
Additional ICU stay (h) 211.0  373.4 197.2  158.2 P ¼ .913
Total ICU stay (h) 76.8  182.4 70.0  143.9 P ¼ .583
Length of stay (d) 13.5  7.5 11.8  7.1 P ¼ .264
Readmission to ICU (%) 14 (4.6%) 14 (3.1%) P ¼ .062
Low cardiac output syndrome 18 (5.9%) 15 (3.3%) P ¼ .025
IABP perioperatively (%) 16 (5.2%) 8 (1.8%) P ¼ .0025
Reoperation for bleeding (%) 18 (5.9% 17 (3.8%) P ¼ .022
Stroke (%) 6 (1.9%) 8 (1.7%) P ¼ .216
Postoperative atrial
fibrillation (%)
98 (32%) 113 (25%) P ¼ .319
PCI, Percutaneous coronary intervention; CPB, cardiopulmonary bypass; OPCAB,
off-pump coronary artery bypass; ICU, intensive care unit; IABP, intraaortic balloon
pump.Cardiovascular Surgery c Volume 137, Number 4 849
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D of myocardial infarction history has been noted in the PCI
group. The higher numbers of myocardial infarction both be-
fore and after PCI suggest an aggressive form of coronary
artery disease that could be related to the existence of unsta-
ble or ruptured coronary plaques. The lower baseline ejec-
tion fraction in the study group can be attributed to the
loss of contractile elements after myocardial infarction, ap-
proximately one third of which took place during the interval
between PCI and CABG. The higher incidence of intraoper-
ative myocardial infarction, low output syndrome, and
the need for IABP perioperatively suggest that the increased
perioperative risk may be associated with preexisting
FIGURE 2. Incidence of (A) perioperative myocardial infarction and (B)
MACE in patients with and without history of PCI who underwent
CABG. PCI, Percutaneous coronary intervention; MI, myocardial infarc-
tion; MACE, major adverse cardiac event.
FIGURE 1. Perioperative and 30-mortality rates in patients with and with-
out history of PCI after CABG. PCI, Percutaneous coronary intervention.850 The Journal of Thoracic and Cardiovascular SuPCI-induced myocardial damage or perioperative stent
thrombosis even in patients without a history of myocardial
infarction. Incidental minor side-branch occlusion has been
postulated to aggravate periprocedural myocardial injury,
especially in complex type C stenoses requiring multiple
stenting or use of long stents, and has been reported to occur
in 11% of patients after PCI.17,18 Lesions with a high burden
of plaque have been associated with an increased risk of
myocardial necrosis in the distal area as a result of distal mi-
croembolization.19,20 Thielmann and colleagues16 have re-
ported an even worse outcome of diabetic patients with
a history of PCI who undergo coronary revascularization
surgery. High mortality and MACE rates of approximately
8% and 14%, respectively, demonstrate that diabetic pa-
tients have a significant disadvantage with regard to the
long-term outcome after primary PCI.
Another important finding of our study was that preoper-
ative risk assessment using EuroSCORE did not predict
perioperative outcome. Although both patient groups were
matched in terms of age, gender, and EuroSCORE-mediated
risk stratification, the perioperative outcome was signifi-
cantly worse in the PCI group. This is attributed to the fact
that EuroSCORE does not take into consideration previous
PCI in calculating risk of cardiac surgery. None of the avail-
able risk analysis models include previous PCI in risk strat-
ification for CABG.21 In the Society of Thoracic Surgeons
database, risk analysis for previous PCI is included in the
data acquisition; however, it has no influence on the risk
stratification model.22 On the other hand, almost all models
used for preoperative stratification, including EuroSCORE,
take into consideration preoperative ejection fraction and
TABLE 5. Perioperative mortality and outcome in diabetic patients
with and without history of percutaneous coronary intervention after




(n ¼ 112) P value
Preoperative ejection fraction 42  12 51  16 P ¼ .004
Total ventilation time (h) 86  134 60  160 P ¼ .084
Total ICU stay (h) 134  304 102  218 P ¼ .355
Length of stay (d) 14.3  6.2 12.8  7.4 P ¼ .413
Low cardiac output syndrome 4 (6.7%) 4 (3.6%) P ¼ .031
IABP perioperatively (%) 7 (11.7%) 10 (8.9%) P ¼ .034
Reoperation for bleeding (%) 6 (10%) 5 (4.4%) P ¼ .021
Stroke (%) 1 (1.7%) 1 (0.9%) P ¼ .580
Perioperative mortality (%) 3 (5%) 2 (1.8%) P ¼ .013
30-d mortality (%) 2 (3.3%) 2 (1.8%) P ¼ .034
Perioperative myocardial
infarction (%)
5 (8.3%) 2 (1.8%) P ¼ .002
MACE (%) 6 (10%) 4 (3.6%) P ¼ .003
Renal failure (%) 5 (8.3%) 6 (5.4%) P ¼ .027
Dialysis (%) 4 (6.7%) 4 (3.6%) P ¼ .015
In-hospital complications (%) 28 (47%) 31 (28%) P ¼ .023
PCI, Percutaneous coronary intervention; ICU, intensive care unit; IABP, intraaortic
balloon pump; MACE, major adverse cardiac event.rgery c April 2009
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Dhistory of myocardial infarction, both of which were more
frequently seen in the PCI group. Higher incidence of preop-
erative myocardial infarction may be associated with more
aggressive disease, incomplete revascularization at primary
PCI,23 or stent therapy failure, including stent thrombosis.24
Our study demonstrated a higher incidence of bleeding
complications, including reoperations for bleeding and peri-
operative use of blood products in patients with a history of
PCI. A closer look at patients’ preoperative characteristics
reveals that patients in the PCI group were more often re-
ceiving platelet anti-aggregation therapy; the mean interval
from PCI to CABG was approximately 9 months. Data
from on- and off-pump coronary surgery suggest that clopi-
dogrel or aspirin premedication in CABG is an independent
predictive factor for increased bleeding complications and
reoperation for bleeding.25,26 Noteworthy antiplatelet medi-
cation was discontinued in all patients included in our series
except for patients with high-risk coronary anatomy or his-
tory of PCI with bare metal or drug-eluting stent(s) for a max-
imum of 6 or 12 months, respectively, according to the
guidelines of the American Heart Association and the Amer-
ican College of Cardiology.27
The higher incidence of renal complication detected in the
PCI group was not surprising, given the higher incidence of
reoperation for bleeding and the higher incidence of perio-
perative low output syndrome in the PCI group. Hypovole-
mic shock and acute heart failure are 2 independent risk
factors for the development of acute renal failure in patients
with preoperatively normal renal function mostly due to pre-
renal cause.28
Study Limitations
Although this study was designed to avoid patient selec-
tion bias, it is still based on a retrospective analysis, which
may make publication bias inevitable. Repeat PCI is an in-
dependent risk factor for perioperative mortality and mor-
bidity in elective CABG. Although we included data from
repeat PCIs, we did not perform a separate statistical analysis
because this topic has been addressed in a previous study.11
Repeat PCI in patients may help to identify a specific high-
risk population within the PCI group with an aggressive
form of coronary artery disease. The retrospective design
of the study and the inclusion of only a relatively low num-
ber of patients from a single center should be considered as
study limitations. However, our strict exclusion criteria
allowed us to concentrate on a homogenous population of
patients with new onset of coronary artery disease. The
difference in preoperative ejection fraction between the 2
groups is not expected to bias the results because it accounts
for only 1 point of the calculated linear EuroSCORE risk.
CONCLUSIONS
The study results demonstrated that a positive history of PCI
had a significantly negative effect on the perioperative out-The Journal of Thoracic and Ccome after CABG. Higher mortality rates were observed,
and these patients had a higher risk for myocardial, renal,
and bleeding complications, which may also have a negative
impact on the long-term results. Our results provide evidence
that higher perioperative mortality is associated with both
myocardial dysfunction and bleeding complications. Preoper-
ative risk evaluation using EuroSCORE did not predict the ac-
tual perioperative outcome, because previous PCI intervention
is not taken into consideration as the most effective risk-strat-
ification tool. Our study may have a significant impact on the
treatment of coronary artery disease as it provides evidence
that some current practice strategies, such as incomplete revas-
cularization or procrastination of surgical revascularization,
lead to a significantly worse perioperative outcome.
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